Literature DB >> 18554814

Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons.

R V Frolov1, M M Slaughter, S Singh.   

Abstract

Accumulating evidence suggests that the side effects of celecoxib, widely used to treat muscle and joint pain, may be mediated in part through cyclooxygenase-2 (COX-2) independent mechanisms, such as inhibition of ion channels. In this study we report effects of celecoxib on ionic currents and neuronal activity in isolated rat retinal neurons. We found that celecoxib suppressed voltage-gated potassium currents in retinal bipolar cells with an effective concentration to inhibit 50% of function (EC(50)) of 5.5 microM. In retinal amacrine and ganglion cells, celecoxib inhibited voltage-dependent sodium channels with an EC(50) of 5.2 microM, and voltage-dependent transient and sustained potassium currents with EC(50)s of 16.3 and 9.1 microM, respectively. Notably, the rate of spontaneous spike activity was dramatically suppressed in ganglion and amacrine cells with an EC(50) of 0.76 microM. All actions of celecoxib on ionic currents and action potentials occurred from the extracellular side and were completely reversible. These findings indicate that inhibition of ion channels by celecoxib in the CNS may affect neuronal function at clinically relevant concentrations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18554814      PMCID: PMC2579776          DOI: 10.1016/j.neuroscience.2008.05.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  23 in total

Review 1.  Celecoxib, rofecoxib, and acute temporary visual impairment.

Authors:  David Morris Coulter; David Walter John Clark; Ruth Lesley Savage
Journal:  BMJ       Date:  2003-11-22

2.  Spontaneous activity of solitary dopaminergic cells of the retina.

Authors:  A Feigenspan; S Gustincich; B P Bean; E Raviola
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

Review 3.  Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.

Authors:  N M Davies; A J McLachlan; R O Day; K M Williams
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

4.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2.

Authors:  A S Kalgutkar; B C Crews; S W Rowlinson; C Garner; K Seibert; L J Marnett
Journal:  Science       Date:  1998-05-22       Impact factor: 47.728

5.  Developmental changes in voltage-activated potassium currents of rat retinal ganglion cells.

Authors:  D F Reiff; E Guenther
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Tetrodotoxin-resistant action potentials in dorsal root ganglion neurons are blocked by local anesthetics.

Authors:  Andreas Scholz; Werner Vogel
Journal:  Pain       Date:  2000-12-15       Impact factor: 6.961

7.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

Authors:  David J Graham; David Campen; Rita Hui; Michele Spence; Craig Cheetham; Gerald Levy; Stanford Shoor; Wayne A Ray
Journal:  Lancet       Date:  2005 Feb 5-11       Impact factor: 79.321

8.  Susceptibilities to and mechanisms of excitotoxic cell death of adult mouse inner retinal neurons in dissociated culture.

Authors:  Xianmin Luo; Akemichi Baba; Toshio Matsuda; Carmelo Romano
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

Review 9.  The development of COX2 inhibitors.

Authors:  Rod J Flower
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

10.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.

Authors:  Alexander Weber; Angela Casini; Andreas Heine; Daniel Kuhn; Claudiu T Supuran; Andrea Scozzafava; Gerhard Klebe
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

View more
  8 in total

1.  Mechanisms of Kv2.1 channel inhibition by celecoxib--modification of gating and channel block.

Authors:  R V Frolov; V E Bondarenko; S Singh
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

2.  Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Bharath K Mani; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

3.  Inhibition of HERG potassium channels by celecoxib and its mechanism.

Authors:  Roman V Frolov; Irina I Ignatova; Satpal Singh
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

4.  Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791.

Authors:  Roman V Frolov; Satpal Singh
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

5.  Evidence of more ion channels inhibited by celecoxib: KV1.3 and L-type Ca(2+) channels.

Authors:  Roman V Frolov; Satpal Singh
Journal:  BMC Res Notes       Date:  2015-03-01

6.  NSAIDs Naproxen, Ibuprofen, Salicylate, and Aspirin Inhibit TRPM7 Channels by Cytosolic Acidification.

Authors:  Rikki Chokshi; Orville Bennett; Tetyana Zhelay; J Ashot Kozak
Journal:  Front Physiol       Date:  2021-10-18       Impact factor: 4.566

7.  The role of potassium channel activation in celecoxib-induced analgesic action.

Authors:  Yao Mi; Xuan Zhang; Fan Zhang; Jinlong Qi; Haixia Gao; Dongyang Huang; Li Li; Hailin Zhang; Xiaona Du
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

8.  Celecoxib reduces cortical spreading depression-induced macrophage activation and dilatation of dural but not pial arteries in rodents: implications for mechanism of action in terminating migraine attacks.

Authors:  Aaron J Schain; Agustin Melo-Carrillo; Sait Ashina; Andrew M Strassman; Rami Burstein
Journal:  Pain       Date:  2020-05       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.